June 2019 - Volume 3 - Issue - Contributor Index

Author:
Gašic, V.
Author:
Gaartman, A.
Author:
Gabarros, M.
Author:
Gabbasova, S.
Author:
Gabcova, G.
Author:
Gabdoulline, R.
Author:
Gabeeva, N.

RESULTS OF TREATMENT PATIENTS OF MANTLE CELL LYMPHOMA DEPENDING ON THE MUTATIONAL STATUS OF THE TP53 GENE: PB2016

Koroleva, D.; Zvonkov, E.; Gabeeva, N.; More

HemaSphere. 3:912, June 2019.

Author:
Gabellini, D.
Author:
gaber, M.
Author:
Gabillaud, C.

B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS: PB1868

Chapiro, E.; Diop, K.; Dessen, P.; More

HemaSphere. 3:851-852, June 2019.

Author:
Gablo, N.
Author:
Gabriel, J.
Author:
Gabriel, L. R.

OUTCOME IN TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA IN LATIN AMERICA. AN INTERNATIONAL STUDY OF GELAMM: PS1402

Peña, C.; Schutz, N. P.; Bove, V.; More

HemaSphere. 3:643-644, June 2019.

Author:
Gabrion, A.

RED BLOOD CELLS PROPERTIES IN PATIENTS WITH SICKLE CELL DISEASE TREATED WITH LENTIGLOBIN GENE THERAPY IN THE HGB-205 TRIAL: PF441

Magrin, E.; Semeraro, M.; Hebert, N.; More

HemaSphere. 3:173-174, June 2019.

Author:
Gachard, N.
Author:
Gade, A.
Author:
Gadisseur, A.
Author:
Gafarova, S.
Author:
Gaffo, E.
Author:
Gagliardi, A.
Author:
Gaidano, G.

THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL: S104

Tiacci, E.; De Carolis, L.; Simonetti, E.; More

HemaSphere. 3:3, June 2019.

UPDATE OF THE SINGLE-ARM PHASE II L-MIND STUDY OF MOR208 PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: HIGH OVERALL RESPONSE RATES IN PATIENT SUBGROUPS WITH POOR PROGNOSIS: PF296

Duell, J.; Maddocks, K.; Barca, González E.; More

HemaSphere. 3:100, June 2019.

PROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH “BORDERLINE” PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: PF365

Raponi, S.; Ilari, C.; Della Starza, I.; More

HemaSphere. 3:134-135, June 2019.

IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). PRELIMINARY RESULTS FROM THE GIMEMA LLC1114 STUDY: PF375

Mauro, F. R.; Molica, S.; Paoloni, F.; More

HemaSphere. 3:139, June 2019.

SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY: PF586

Larocca, A.; Salvini, M.; Gaidano, G.; More

HemaSphere. 3:244, June 2019.

COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL: PS1248

Ferrero, S.; Zaccaria, G. M.; Barbero, D.; More

HemaSphere. 3:569-570, June 2019.

Author:
Gaidzik, V. I.

MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA (AML) WITH T(8;21)(Q22;Q22.1); RUNX1-RUNX1T1: RESULTS OF THE AML STUDY GROUP (AMLSG): S1616

Rücker, F. G.; Agrawal, M.; Corbacioglu, A.; More

HemaSphere. 3:745-746, June 2019.

Author:
Gaillard, B.

B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS: PB1868

Chapiro, E.; Diop, K.; Dessen, P.; More

HemaSphere. 3:851-852, June 2019.

Author:
Gainaru, G.

COMPARISON OF RITUXIMAB DOSE-ADJUSTED EPOCH (R-DA-EPOCH) WITH RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): PF297

Vassilakopoulos, T.; Mellios, Z.; Verigou, E.; More

HemaSphere. 3:100-101, June 2019.

PET-SCAN FOR RESPONSE ASSESSEMENT AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): CLINICAL AND PROGNOSTIC SIGNIFICANCE: PS1089

Vassilakopoulos, T.; Chatzidimitriou, C.; Mellios, Z.; More

HemaSphere. 3:494, June 2019.

Author:
Gaipa, G.

GMP MANUFACTURING OF ALLOGENEIC CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) CYTOKINE INDUCED KILLER (CIK) CELLS WITH SLEEPING BEAUTY (SB) TRANSPOSON FOR ADOPTIVE IMMUNOTHERAPY: PF436

Magnani, C. F.; Gaipa, G.; Belotti, D.; More

HemaSphere. 3:171, June 2019.

Author:
Gajdos, P.
Author:
Gakiopoulou, C.

AN EARLY, WITHIN THE FIRST MONTH, AND DEEP RESPONSE, SHOULD BE THE GOAL OF THERAPY IN AL AMYLOIDOSIS: PS1378

Kastritis, E.; Karatrasoglou, E. A.; Dialoupi, I.; More

HemaSphere. 3:630-631, June 2019.

CONSOLIDATION WITH A SHORT COURSE OF DARATUMUMAB CAN SIGNIFICANTLY IMPROVE COMPLETE RESPONSE RATES IN PATIENTS WITH AL AMYLOIDOSIS OR LCDD: PS1392

Kastritis, E.; Gavriatopoulou, M.; Kostopoulos, I. V.; More

HemaSphere. 3:638-639, June 2019.

PRIMARY TREATMENT OF LIGHT CHAIN (AL) AMYLOIDOSIS WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (VRD): PS1393

Kastritis, E.; Dialoupi, I.; Gavriatopoulou, M.; More

HemaSphere. 3:639, June 2019.

Author:
Gal'tseva, I.
Author:
Galacteros, F.
Author:
galal, S.

THE STAT SIGNALING BIOSIGNATURE OF CD4+ T CELL SUBSETS REFLECT THE IMMUNOGENICITY OF HIGH-RISK MDS AND PREDICT AZACYTIDINE TREATMENT OUTCOME: PF537

Lamprianidou, E.; Kordella, C.; Zoulia, E.; More

HemaSphere. 3:221-222, June 2019.

PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN THE ELRDELRY AND YOUNGER ADULTS: REAL-WORLD COMPARATIVE RETROSPECTIVE STUDY FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY: PF693

Pontikoglou, C.; Kaliafentaki, V.; Stavroulaki, E.; More

HemaSphere. 3:301, June 2019.

IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA - A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP: S840

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3:374-375, June 2019.

Author:
Galassi, L.

EPIDEMIOLOGY AND MANAGEMENT OF LATENT TUBERCULOSIS INFECTION IN ADULT PATIENTS WITH ACUTE LEUKEMIA OR APLASTIC ANEMIA: A RETROSPECTIVE MONOCENTER STUDY: PS1274

Bettelli, F.; Giusti, D.; Morselli, M.; More

HemaSphere. 3:583, June 2019.

Author:
Galaverna, F.
Author:
Galayko, M.

THE LONG-TERM TREATMENT RESULTS OF THE MULTICENTER EUTOS ELN POPULATION-BASED STUDY (EUTOS-PBS) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN RUSSIAN FEDERATION: PF422

Lazareva, O.; Turkina, A.; Chelysheva, E.; More

HemaSphere. 3:164-165, June 2019.

Author:
Gale, D.
Author:
Gale, R.
Author:
Galende, J.

SYNTHETIC LETHAL EFFECTS OF DUAL BCR AND PARP INHIBITION IN PROLIFERATIVE DEL(11Q) CLL CELLS IN THE PRESENCE OF STROMAL STIMULATION: S896

Quijada-Álamo, M.; Hernández-Sánchez, M.; Rodríguez-Vicente, A. E.; More

HemaSphere. 3:403-404, June 2019.

Author:
Galieni, P.

TUMOR CIRCULATING PLASMA CELLS DETECTED BY FLOW CYTOMETRIC SINGLE PLATFORM METHOD ARE RELATED TO NEGATIVE PATIENTS‘ CHARACTERISTICS IN MULTIPLE MYELOMA: PF579

Muccio, V. E.; Gilestro, M.; Saraci, E.; More

HemaSphere. 3:241-242, June 2019.

OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS: PF602

Montefusco, V.; Gay, F.; Spada, S.; More

HemaSphere. 3:254-255, June 2019.

Author:
Galimberti, S.

SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED: S123

Mancini, M.; De Santis, S.; Monaldi, C.; More

HemaSphere. 3:13-14, June 2019.

PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS: PF172

Soverini, S.; Martelli, M.; Bavaro, L.; More

HemaSphere. 3:37-38, June 2019.

RESULTS OF A PROSPECTIVE MULTICENTER STUDY ON PRO-ATHEROTHROMBOTIC EFFECT INDUCED BY TYROSINE-KINASE INHIBITORS FOR FIRST-LINE TREATMENT OF CML PTS (KIARO TRIAL): PF420

Sicuranza, A.; Brambilla, Zuanelli C.; Ferrigno, I.; More

HemaSphere. 3:163-164, June 2019.

Author:
Galinsky, J.
Author:
Galitzia, A.
Author:
Gallamini, A.

FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY: S820

Gallamini, A.; Straus, D.; Dlugosz-Danecka, M.; More

HemaSphere. 3:362-363, June 2019.

DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI-CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI: PS1237

Mazza, R.; Spina, M.; Califano, C.; More

HemaSphere. 3:563-564, June 2019.

Author:
Gallardo, M.
Author:
Gallay, N.

ABNORMAL DNA METHYLATION MODIFIES HOX GENES EXPRESSION IN BONE MARROW MESENCHYMAL STROMAL CELLS OF MYELODYSPLASIAS AND DE NOVO ACUTE MYELOID LEUKEMIAS: PS989

Roux, B.; Picou, F.; Vignon, C.; More

HemaSphere. 3:444, June 2019.

Author:
Gallego, P.
Author:
Galler, C.

GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY: S105

Tausch, E.; Bahlo, J.; Robrecht, S.; More

HemaSphere. 3:4, June 2019.

Author:
Galleu, A.
Author:
Galli, A.
Author:
Galli, E.
Author:
Galli, M.

CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS: S872

Gay, F.; Cerrato, C.; Scalabrini, Rota D.; More

HemaSphere. 3:390-391, June 2019.

Author:
Gallur, L.
Author:
Galson, J.

DEVELOPMENT AND OPTIMISATION OF A FULLY HUMAN FVIII MIMETIC BISPECIFIC ANTIBODY FOR PATIENTS WITH HAEMOPHILIA A: PF338

Wang, W.; Blackwood, J.; Magliozzi, R.; More

HemaSphere. 3:120-121, June 2019.

Author:
Galstyan, G.
Author:
Galtceva, I.

SEQUENTIAL IMPROVEMENTS IN THE OUTCOME OF INTENSIVE INDUCTION CHEMOIMMUNOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH UNTREATED WALDENSTROM MACROGLOBULINEMIA.: PB2017

Grachev, A.; Zvonkov, E.; Ryzhko, V.; More

HemaSphere. 3:912, June 2019.

Author:
Galtseva, I.

PD-1 PATHWAY IS A KEY IMMUNOSUPPRESSIVE MECHANISM IN PATIENTS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH TCR AB-DEPLETION: PF755

Popova, N.; Drokov, M.; Davydova, Y.; More

HemaSphere. 3:331-332, June 2019.

Show: